Microneedle Array Electrodes for Low-Latency Glucose Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional continuous glucose monitoring (CGM) devices suffer from tissue trauma, pain, and limited accuracy due to insertion-related issues and signal latency, failing to timely detect hyperglycemia or hypoglycemia.
Innovation Solution
A microneedle array with insulated distal apices and electrodes on a tapered surface is used to access dermal interstitial fluid, providing accurate and real-time glucose monitoring with reduced pain and improved sensitivity and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional transdermal electrochemical sensors are used for continuous glucose monitoring, then continuous detection capability is achieved, but tissue trauma and pain occur during insertion
Solution Approach 1:
The patent changes the physical parameters of the sensor insertion mechanism by using microneedles with dimensions in the micrometer range (typically 50-500 micrometers in length) instead of conventional larger needles. This parameter change enables penetration of the stratum corneum and access to interstitial fluid while minimizing activation of pain receptors and reducing tissue trauma, thus resolving the contradiction between continuous detection capability and patient comfort.
2Reliability
If conventional CGM sensors are inserted into subcutaneous tissue, then glucose monitoring is enabled, but signal latency occurs due to diffusion time
Solution Approach 1:
The patent transitions from subcutaneous implantation (deeper tissue layer) to intradermal insertion using microneedles (shallower tissue layer). This dimensional change in insertion depth places the sensor closer to the skin surface and nearer to capillary blood flow, reducing the diffusion distance for glucose to reach the sensor. Consequently, signal latency is reduced while maintaining reliable glucose monitoring capability.
3Measurement precision
If microneedle array with insulated distal apices is used, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The patent applies local quality by insulating only the distal apex portion of each microneedle while leaving the shaft and base conductive. This localized insulation at the insertion tip prevents unwanted electrical contact with tissue during penetration, reducing noise and interference. The selective application of insulation only where needed improves measurement precision without requiring complete insulation of the entire microneedle structure, thus limiting the increase in device complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microneedle array enables pain-free, minimally-invasive glucose monitoring with reduced latency and enhanced accuracy, allowing for real-time detection of glucose levels.
Implementation Method 1
accessing dermal interstitial fluid
Implementation Method 2
quantifying one or more analytes in the body fluid using the analyte monitoring device
Data Source
AI summary
Described herein are variations of an analyte monitoring system, including an analyte monitoring device. For example, an analyte monitoring device may include an implantable microneedle array for use in measuring one or more analytes (e.g., glucose), such as in a continuous manner. The microneedle array may include, for example, at least one microneedle including a tapered distal portion having an insulated distal apex, and an electrode on a surface of the tapered distal portion located proximal to the insulated distal apex. At least some of the microneedles may be electrically isolated such that one or more electrodes is individually addressable.